Evidence map›Paper›PMID 40067073›Full record

ArticleCancer reports (Hoboken, N.J.)2025

Evaluation of Mortality Risk Factors in Prostate Cancer: Impact of Demographic, Clinical, Laboratory, Therapeutic, and Trace Element Influences.

Pitchou Mukaz Mbey, Pablo Diasiama Kuntima Diangienda, Olivier Mukuku, Willy Kalau Arung, Célestin Lubaba Banza, Alpha Tsita Mafuta, Mathieu Nkumu Loposso, Bienvenu Massamba Lebwaze, Augustin Maole-Lembe Punga, Guy Ilunga Nday and 1 more

Abstract read
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pitchou Mukaz MbeyDepartment of Surgery, Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.ORCID 0000-0003-3776-383X
Pablo Diasiama Kuntima DiangiendaDepartment of Surgery, Urology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Olivier MukukuInstitut Supérieur Des Techniques Médicales, Lubumbashi, Democratic Republic of the Congo.ORCID 0000-0001-6902-7023
Willy Kalau ArungDepartment of Surgery, Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.
Célestin Lubaba BanzaDepartment of Toxicology, Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.
Alpha Tsita MafutaDepartment of Surgery, Urology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Mathieu Nkumu LopossoDepartment of Surgery, Urology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Bienvenu Massamba LebwazeDepartment of Histopathology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.ORCID 0009-0005-5507-4634
Augustin Maole-Lembe PungaDepartment of Surgery, Urology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Guy Ilunga NdayDepartment of Surgery, Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.
Dieudonné Molamba MoningoDepartment of Surgery, Urology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is a significant contributor to male mortality globally, including in the Democratic Republic of the Congo (DRC). Various factors play a role in its onset and progression. The impact of trace elements and other risk factors on the survival of PCa patients is not extensively studied in this setting. This study aimed to evaluate the effect of demographic characteristics, clinical factors, laboratory investigations, therapeutic aspects, and trace elements on the occurrence of mortality in this disease.

methodsA sample of 94 PCa patients was included in this study. Among them, 22 (23.40%) deceased, while 72 (76.60%) survived during a 5-year follow-up period. Sociodemographic, clinical, laboratory investigations, therapeutic aspects, and trace element levels (in tissues and urine) were gathered and analyzed. Statistical analyses were conducted to pinpoint mortality predictors, with Cox regression utilized to account for variable impacts.

resultsIn multivariate analyses, age (adjusted hazard ratio [aHR] = 1.06; p = 0.025), prostate-specific antigen [PSA] (aHR = 1.01; p = 0.037), hemoglobin (aHR = 0.69; p = 0.010), and the presence of metastases (aHR = 3.83; p = 0.037) were identified as significant predictors of mortality. Furthermore, elevated levels of urinary strontium (aHR = 1.08; p = 0.016), manganese (aHR = 1.51; p = 0.003), and cobalt (aHR = 1.30; p = 0.030) were linked to an increased risk of mortality. Conversely, higher levels of tissue copper were associated with a reduced risk of death (aHR = 0.99; p = 0.045).

conclusionThe results obtained have indicated that specific trace elements, along with age, PSA level, hemoglobin level, and the presence of metastases, are predictive of mortality in PCa patients in the DRC. Enhanced comprehension and control of these factors may lead to improved survival outcomes. Additional investigation is warranted to validate these correlations and to facilitate the development of therapeutic interventions.

Indexed as

Prostatic NeoplasmsTrace ElementsAgedAge FactorsDemocratic Republic of the CongoFollow-Up StudiesHumansMaleMiddle AgedPrognosisProstate-Specific AntigenRisk FactorsProstate-Specific AntigenTrace Elementsmortalityprostate cancerrisk factorstrace elements

Identifiers

PMID40067073
PMCPMC11894822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.